Pablo Sarobe Ugarriza-rekin lankidetzan egindako argitalpenak (56)

2017

  1. Blockage of FOXP3 transcription factor dimerization and FOXP3/AML1 interaction inhibits T regulatory cell activity: sequence optimization of a peptide inhibitor

    Oncotarget, Vol. 8, Núm. 42, pp. 71709-71724

2016

  1. Gene expression analysis during acute hepatitis C virus infection associates dendritic cell activation with viral clearance

    Journal of Medical Virology, Vol. 88, Núm. 5, pp. 843-851

2015

  1. Clinical testing of a dendritic cell targeted therapeutic vaccine in patients with chronic hepatitis C virus infection

    Molecular Therapy - Methods and Clinical Development, Vol. 2, pp. 15006

  2. Inhibition of FOXP3/NFAT interaction enhances T cell function after TCR stimulation

    Journal of Immunology, Vol. 195, Núm. 7, pp. 3180-3189

2014

  1. Characterization of the CD40L/Oncostatin M/Oncostatin M receptor axis as an antiviral and immunostimulatory system disrupted in chronic HCV infection

    Journal of Hepatology, Vol. 60, Núm. 3, pp. 482-489

  2. Dysregulation of interferon regulatory factors impairs the expression of immunostimulatory molecules in hepatitis C virus genotype 1-infected hepatocytes

    Gut, Vol. 63, Núm. 4, pp. 665-673

2013

  1. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C

    Journal of Hepatology, Vol. 59, Núm. 1, pp. 81-88

  2. A fusion protein between streptavidin and the endogenous tlr4 ligand EDA targets biotinylated antigens to dendritic cells and induces t cell responses in vivo

    BioMed Research International, Vol. 2013

  3. Helper cell-independent antitumor activity of potent CD8+ T cell epitope peptide vaccines is dependent upon CD40L

    OncoImmunology, Vol. 2, Núm. 12, pp. 1-11

2012

  1. Combination of a TLR4 ligand and anaphylatoxin C5a for the induction of antigen-specific cytotoxic T cell responses

    Vaccine, Vol. 30, Núm. 18, pp. 2848-2858

  2. Eradication of large tumors expressing human papillomavirus E7 protein by therapeutic vaccination with E7 fused to the extra domain a from fibronectin

    International Journal of Cancer, Vol. 131, Núm. 3, pp. 641-651

2011

  1. Adjuvant combination and antigen targeting as a strategy to induce polyfunctional and high-avidity T-cell responses against poorly immunogenic tumors

    Cancer Research, Vol. 71, Núm. 9, pp. 3214-3224

  2. Enhanced T cell responses against hepatitis C virus by ex vivo targeting of adenoviral particles to dendritic cells

    Hepatology, Vol. 54, Núm. 1, pp. 28-37

  3. Hepatitis C virus induces the expression of CCL17 and CCL22 chemokines that attract regulatory T cells to the site of infection

    Journal of Hepatology, Vol. 54, Núm. 3, pp. 422-431

  4. Improved dendritic cell-based immunization against hepatitis C virus using peptide inhibitors of interleukin 10

    Hepatology, Vol. 53, Núm. 1, pp. 23-31

2010

  1. A peptide inhibitor of FOXP3 impairs regulatory T cell activity and improves vaccine efficacy in mice

    Journal of Immunology, Vol. 185, Núm. 9, pp. 5150-5159

  2. Identification of CD4+ and CD8+ T cell epitopes of woodchuck hepatitis virus core and surface antigens in BALB/c mice

    Vaccine, Vol. 28, Núm. 32, pp. 5323-5331

  3. Tumor therapy in mice by using a tumor antigen linked to modulin peptides from Staphylococcus epidermidis

    Vaccine, Vol. 28, Núm. 44, pp. 7146-7154

2009

  1. Immunization against hepatitis C virus with a fusion protein containing the extra domain A from fibronectin and the hepatitis C virus NS3 protein

    Journal of Hepatology, Vol. 51, Núm. 3, pp. 520-527

  2. Oncostatin M enhances the antiviral effects of type I interferon and activates immunostimulatory functions in liver epithelial cells

    Journal of Virology, Vol. 83, Núm. 7, pp. 3298-3311